- 39 Downloads
The newly introduced cyclo-oxygenase-2 (COX-2) inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs) have been established as effective agents in treating arthritic conditions, while greatly reducing the gastrointestinal adverse effects of traditional NSAIDs. There are expectations that NSAIDs will be useful in the treatment of Alzheimer’s disease (AD), and that COX-2 inhibitors might have a role. However, a recently reported clinical trial of a COX-2 inhibitor in AD indicated that it was neither protective nor did it accelerate the decline. The expectations were based on pathological evidence of inflammatory changes associated with AD lesions and epidemiological evidence of a reduced prevalence of AD in populations taking NSAIDs. They were supported by preliminary evidence showing efficacy of NSAIDs in treating patients with AD. These data are based on the use of traditional NSAIDs.
Whether COX-2 inhibitors would be similarly effective was uncertain since COX-2 is constitutively expressed in neurons. Animal experiments suggest that COX-2 may be performing adaptive functions associated with normal neurons and protective functions associated with stressed neurons. These results emphasise that the appropriate target for NSAID trials in AD is COX-1, but they also indicate that there would be no contraindication to the use of those traditional NSAIDs which have mixed COX-l/COX-2 inhibiting activity.
KeywordsCelecoxib Microglial Activation Misoprostol Nimesulide Meloxicam
Our work on Alzheimer disease has been supported by grants from the Alzheimer Societies of British Columbia and Canada, and the Jack Brown and Family A.D. Research Fund, as well as donations from individual British Columbians.
- 4.Robitaille A. Improved nonsteroidal anti-inflammatories. Can J Contin Med Educ 1998 July: 85–97Google Scholar
- 6.Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 1997; 24Suppl. 49: 20–4Google Scholar
- 7.Lipsky PE, Isakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 1997; 24Suppl. 49: 9–14Google Scholar
- 16.Sainali SM, Ingram DM, Talwaker S, et al. Results of a double-blind, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer’s disease [abstract]. 6th International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy; 2000 Apr 5–8; StockholmGoogle Scholar
- 18.Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24Suppl. 49: 15–9Google Scholar
- 26.Wallace JL, Chin BC. New generation NSAIDs: the benefits without the risks. Drugs Today 1997 Jul–Aug; 33(6): 371–8Google Scholar
- 46.Penning TD, Talley JJ, Bertenshaw ST, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-5-(4-methylphe-nyl)-3-(trifluoromethyl)-lH-pyrazol-l-yl]benzenesulfonam ide (SC-58635, Celecoxib). J Med Chem 1997; 40: 1347–65PubMedCrossRefGoogle Scholar